Although the conventional CEA EIA significantly discriminate (p < 0.05) CRC samples from benign and healthy control, it is elevated only in 4 out of 11 early-stage CRC with only one early-stage serum showing above conventional cut-off (5 ng/mL) of CEA EIA. This evidence concerns the gene CEACAM5 and colorectal carcinoma.